STRS Ohio’s Royalty Pharma RPRX Stock Holding History

STRS Ohio’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$522K	Buy	9,307 +112	+1%	+$5.83K	﹤0.01%	1130
2026 Q1	$441K	Sell	9,195 -123	-1%	-$5.39K	﹤0.01%	1147
2025 Q4	$360K	Buy	9,318 +252	+3%	+$9.61K	﹤0.01%	1235
2025 Q3	$320K	Sell	9,066 -76,782	-89%	-$2.78M	﹤0.01%	1305
2025 Q2	$3.09M	Buy	85,848 +25,022	+41%	+$829K	0.01%	554
2025 Q1	$1.89M	Sell	60,826 -50,380	-45%	-$1.6M	0.01%	621
2024 Q4	$2.84M	Buy	+111,206	New	+$2.95M	0.01%	554
2023 Q2	–	Sell	-38,670	Closed	-$1.39M	–	2075
2023 Q1	$1.39M	Sell	38,670 -11,800	-23%	-$438K	0.01%	797
2022 Q4	$1.99M	Buy	50,470 +12,375	+32%	+$517K	0.01%	626
2022 Q3	$1.53M	Sell	38,095 -4,883	-11%	-$209K	0.01%	682
2022 Q2	$1.81M	Buy	+42,978	New	+$1.76M	0.01%	639

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

STRS Ohio's RPRX Position: Q2 2026 in Review

STRS Ohio increased its Royalty Pharma (RPRX) stake by 1.2% in Q2 2026, buying an estimated $5.83K and bringing the position to 9,307 shares worth $522K. The position accounts for ﹤0.01% of the portfolio, ranked #1130.

STRS Ohio first reported a position in RPRX in Q2 2022 and has held it in 11 quarters since. The position peaked at $3.09M in Q2 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

STRS Ohio held 9,307 shares of Royalty Pharma worth $522K as of Q2 2026.
STRS Ohio bought 112 Royalty Pharma shares in Q2 2026, an estimated $5.83K.
Royalty Pharma made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1130 holding.
STRS Ohio first reported a position in Royalty Pharma in Q2 2022 and has held it in 11 quarters since.
STRS Ohio's Royalty Pharma position peaked at $3.09M in Q2 2025.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.